Cargando…

Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer

BACKGROUND: Although BRCA1 has been extensively studied for its role as a tumour-suppressor protein, the role of BRCA1 subcellular localisation in oncogenesis and tumour progression has remained unclear. This study explores the impact of BRCA1 mislocalisation on clinical outcomes in breast cancer. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santivasi, W L, Wang, H, Wang, T, Yang, Q, Mo, X, Brogi, E, Haffty, B G, Chakravarthy, A B, Xia, Fen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522623/ https://www.ncbi.nlm.nih.gov/pubmed/26057449 http://dx.doi.org/10.1038/bjc.2015.208

Ejemplares similares

Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours
por: Caiazza, F, et al.
Publicado: (2011)

Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers
por: Clarke, C L, et al.
Publicado: (2006)

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
por: Tiseo, M, et al.
Publicado: (2013)

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011)

DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers
por: Kotsopoulos, J, et al.
Publicado: (2007)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

BRCA1 tumours correlate with a HIF-1α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression
por: Yan, M, et al.
Publicado: (2009)

Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers
por: Shao, R, et al.
Publicado: (2011)

Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma
por: Wang, T, et al.
Publicado: (2010)

Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients
por: Payne, R E, et al.
Publicado: (2012)

Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system
por: Wheeler, S E, et al.
Publicado: (2014)

Nuclear CSPP1 expression defined subtypes of basal-like breast cancer
por: Sternemalm, J, et al.
Publicado: (2014)

Cancer-associated fibroblasts induce epithelial–mesenchymal transition of breast cancer cells through paracrine TGF-β signalling
por: Yu, Y, et al.
Publicado: (2014)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis
por: Cao, R, et al.
Publicado: (2014)

Expression of interferon-γ in human adrenal gland and kidney tumours
por: Li, Q, et al.
Publicado: (2007)

Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer
por: Wang, N, et al.
Publicado: (2014)

Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer
por: Palmieri, C, et al.
Publicado: (2013)

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
por: Zidan, J, et al.
Publicado: (2005)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression
por: Wyler, L, et al.
Publicado: (2014)

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers
por: Klimov, Sergey, et al.
Publicado: (2017)

High FoxP3 expression in tumour cells predicts better survival in gastric cancer and its role in tumour microenvironment
por: Ma, G-F, et al.
Publicado: (2014)

Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing
por: Kalirai, H, et al.
Publicado: (2014)

Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion
por: Fry, Simon A, et al.
Publicado: (2016)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ
por: Wülfing, P, et al.
Publicado: (2005)

Tumour-initiating capacity is independent of epithelial–mesenchymal transition status in breast cancer cell lines
por: Xie, G, et al.
Publicado: (2014)

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
por: Frattini, M, et al.
Publicado: (2007)

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
por: Dotan, E, et al.
Publicado: (2012)

MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways
por: Li, X-J, et al.
Publicado: (2013)

BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours
por: D'Arcy, V, et al.
Publicado: (2008)

Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials
por: Som, A, et al.
Publicado: (2012)

Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer
por: Yang, Q, et al.
Publicado: (2014)

Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma
por: Végran, F, et al.
Publicado: (2009)

Astronomical algorithms for automated analysis of tissue protein expression in breast cancer
por: Ali, H R, et al.
Publicado: (2013)

MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer
por: Xu, X T, et al.
Publicado: (2012)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype
por: Van der Auwera, I, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_gt291gh939nksq2g9t57pd4ikb